AXLA

Axcella Health Inc. (AXLA) | Rumor.io

Axcella Health

AXLA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about AXLA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Oct 5

Axcella Health Inc. (AXLA) price is moving significantly, potentially setting up a squeeze.
The stock has high short interest, which could contribute to a squeeze and potentially drive the price up to $60.
Based on technical indicators, the Relative Strength Index (RSI) is expected to reach 75+ soon, indicating a possible price increase.

Generated by AI

Sentiment

Of the messages about AXLA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0%
Bearish	—	—	—	100%

Bullish· Sep 29

Axcella Health Inc. ($AXLA) is setting up for a big squeeze with a low float and strong buying pressure.
A bullish pennant is forming, indicating a potential breakout above the strong resistance at $11-$11.50.
The stock has been consolidating and is ready to push through $11, with a strong short squeeze play and potential for a significant price increase.

Bearish· Sep 28

$AXLA's recent price action may be unsustainable, as reverse splits often fizzle out abruptly.
$AXLA's price has not held up to expectations, and its thin trading volume may indicate a lack of buying interest.
$AXLA's bearish comments and short interest may lead to a significant price drop, with some predicting a potential fall to zero.

Generated by AI

Topics

Of the messages about AXLA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Aug 29

Axcella Health Inc. (AXLA) was granted a patent by the U.S. Patent and Trademark Office for its lead candidate AXA1125 to treat long COVID fatigue.
The patent covers methods of use of AXA1125 for treating post-acute sequelae of COVID-19, particularly fatigue, and has an expected expiration in 2042.
AXLA shares surged after the patent news, with some investors predicting multi-dollar gains in the future.

Technical Analysis· Sep 13

$AXLA has shown a potential C&H breakout, with a possible trend continuation if it holds above $1.20.
The next pivotal trigger for $AXLA is expected to occur at $1.50, setting up a double top test at $1.65, with signs of market exhaustion below $1.20.
$AXLA is showing signs of exhaustion, having failed to break through $1.40, with a possible new support level forming, and a momentum trigger adjusted from $1.50 to $1.45 for a high test at $1.60+.

Generated by AI

Community

Of the messages about AXLA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0%
Newcomers	—	—	—	100%

Regulars· Sep 15

$AXLA is experiencing a 9.31% price increase, potentially due to positive news and development, with a momentum trigger at $0.87 for a potential rise to $0.90 or above.
The stock has shown signs of exhaustion after reaching an intraday high of $0.86, but the $0.87 momentum trigger remains a reliable entry point for a potential rise.
$AXLA's implementation of a 1-for-25 reverse stock split has led to a significant decline in shares, with the stock down (-26.7% pre-split).

Newcomers· Sep 22

$AXLA has seen significant price appreciation, with a +10% gain for one account and a 21% short interest, indicating potential for further volatility.
A small float of 3 million shares, resulting from a recent reverse split, has led some to consider $AXLA a good squeeze candidate, although its short interest is still relatively high at 37%.
Newcomers are speculating about the potential for a 20%+ spike in $AXLA's price next week, based on a bullish trend and the possibility of parabolic short traders being caught offside.

Generated by AI

News

SK Hynix—which supplies memory chips to Nvidia—is about to test Wall Street's appetite for the next wave of tech IPOs | Fortune

The Korean memory giant’s nearly 8-fold stock surge and $28 billion U.S. listing will show how much AI optimism is still left in the market.

2mo agoFortune

Also Discussed

Investors talking about AXLA also mention

#	Name	Attention
1	Avalo Therapeutics, Inc.AVTX	0%0
2	ICCT - iCoreConnect Inc.	——
3	BNOX - Bionomics Limited	——
4	NVOS - Novo Integrated Sciences, Inc.	——
5	EBET - EBET, Inc.	——
6	NBSE - NeuBase Therapeutics, Inc.	——
7	EZGO Technologies Ltd.EZGO	0%0
8	Evelo Biosciences Inc.EVLO	0%0
9	Femasys Inc.FEMY	0%+0
10	noco-noco Inc.NCNC	0%0

Axcella Health Inc.

Location

Social

What share of all stock conversation is about AXLA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Oct 5

Axcella Health Inc. (AXLA) price is moving significantly, potentially setting up a squeeze.
The stock has high short interest, which could contribute to a squeeze and potentially drive the price up to $60.
Based on technical indicators, the Relative Strength Index (RSI) is expected to reach 75+ soon, indicating a possible price increase.

Generated by AI

Sentiment

Of the messages about AXLA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0%
Bearish	—	—	—	100%

Bullish· Sep 29

Axcella Health Inc. ($AXLA) is setting up for a big squeeze with a low float and strong buying pressure.
A bullish pennant is forming, indicating a potential breakout above the strong resistance at $11-$11.50.
The stock has been consolidating and is ready to push through $11, with a strong short squeeze play and potential for a significant price increase.

Bearish· Sep 28

$AXLA's recent price action may be unsustainable, as reverse splits often fizzle out abruptly.
$AXLA's price has not held up to expectations, and its thin trading volume may indicate a lack of buying interest.
$AXLA's bearish comments and short interest may lead to a significant price drop, with some predicting a potential fall to zero.

Generated by AI

Topics

Of the messages about AXLA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Aug 29

Axcella Health Inc. (AXLA) was granted a patent by the U.S. Patent and Trademark Office for its lead candidate AXA1125 to treat long COVID fatigue.
The patent covers methods of use of AXA1125 for treating post-acute sequelae of COVID-19, particularly fatigue, and has an expected expiration in 2042.
AXLA shares surged after the patent news, with some investors predicting multi-dollar gains in the future.

Technical Analysis· Sep 13

$AXLA has shown a potential C&H breakout, with a possible trend continuation if it holds above $1.20.
The next pivotal trigger for $AXLA is expected to occur at $1.50, setting up a double top test at $1.65, with signs of market exhaustion below $1.20.
$AXLA is showing signs of exhaustion, having failed to break through $1.40, with a possible new support level forming, and a momentum trigger adjusted from $1.50 to $1.45 for a high test at $1.60+.

Generated by AI

Community

Of the messages about AXLA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0%
Newcomers	—	—	—	100%

Regulars· Sep 15

$AXLA is experiencing a 9.31% price increase, potentially due to positive news and development, with a momentum trigger at $0.87 for a potential rise to $0.90 or above.
The stock has shown signs of exhaustion after reaching an intraday high of $0.86, but the $0.87 momentum trigger remains a reliable entry point for a potential rise.
$AXLA's implementation of a 1-for-25 reverse stock split has led to a significant decline in shares, with the stock down (-26.7% pre-split).

Newcomers· Sep 22

$AXLA has seen significant price appreciation, with a +10% gain for one account and a 21% short interest, indicating potential for further volatility.
A small float of 3 million shares, resulting from a recent reverse split, has led some to consider $AXLA a good squeeze candidate, although its short interest is still relatively high at 37%.
Newcomers are speculating about the potential for a 20%+ spike in $AXLA's price next week, based on a bullish trend and the possibility of parabolic short traders being caught offside.

Generated by AI

Axcella Health

Social

Oct 5

Bullish· Sep 29

Bearish· Sep 28

Announcements· Aug 29

Technical Analysis· Sep 13

Regulars· Sep 15

Newcomers· Sep 22

SK Hynix—which supplies memory chips to Nvidia—is about to test Wall Street's appetite for the next wave of tech IPOs | Fortune

Also Discussed

Axcella Health Inc.

Company Information

Location

SK Hynix—which supplies memory chips to Nvidia—is about to test Wall Street's appetite for the next wave of tech IPOs | Fortune

Also Discussed

Social

Oct 5

Bullish· Sep 29

Bearish· Sep 28

Announcements· Aug 29

Technical Analysis· Sep 13

Regulars· Sep 15

Newcomers· Sep 22